You can now read 5 articles in a month for free on BostonGlobe.com. Read as much as you want anywhere and anytime for just 99¢.

Red Sox Live

4

5

Final

Ironwood’s drug for IBS with constipation gets regulatory approval in Europe

Ironwood Pharmaceuticals Inc. of Cambridge and its European partner Almirall S.A. said Wednesday that Ironwood’s drug for irritable bowel syndrome with constipation has been approved by European regulators.

That same drug is about to go onto the US market, following approval by the Food and Drug Administration earlier this year. According to a recent Globe story, irritable bowel syndrome, or IBS, afflicts 30 million to 40 million Americans. Given the number of people affected, the drug has the potential to be a blockbuster, ringing up annual sales of $1 billion or more.

Continue reading below

The drug will be marketed under one brand name in the US, Linzess, and under another brand name --- Constella --- in Europe.

The active ingredient in Linzess and Constella is linaclotide, and it has been approved for the treatment of moderate to severe irritable bowel syndrome with constipation in adults, Ironwood and Almirall said in a press release. (Irritable bowel syndrome with constipation is also known as IBS-C.)

In 2009, Almirall and Ironwood signed a license agreement that gives Almirall exclusive marketing rights for linaclotide in all European Union member states, plus Russia, Turkey, as well as several other countries in Europe.

Almirall expects to begin launching Constella in Europe in the first half of 2013.

Chris Reidy can be reached at reidy@globe.com.
Loading comments...
Subscriber Log In

We hope you've enjoyed your 5 free articles'

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com
Already a subscriber?
Your city. Your stories. Your Globe.
Yours FREE for two weeks.
Enjoy free unlimited access to Globe.com for the next two weeks.
Limited time only - No credit card required!
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.
Thanks & Welcome to Globe.com
You now have unlimited access for the next two weeks.
BostonGlobe.com complimentary digital access has been provided to you, without a subscription, for free starting today and ending in 14 days. After the free trial period, your free BostonGlobe.com digital access will stop immediately unless you sign up for BostonGlobe.com digital subscription. Current print and digital subscribers are not eligible for the free trial.